CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors

AIDS

Volumn 14, Issue 2, 2000, Pages 103-108

  Clegg, Alison O ^b   Ashton, Lesley J ^a   Biti, Robyn A ^b   Badhwar, Prerna ^b   Williamson, Peter ^b   Kaldor, John M ^a   Stewart, Graeme J ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CCR 5 promoter polymorphism; Disease progression; Long term non progression

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DISEASE COURSE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; T LYMPHOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; GENOTYPE; HETEROZYGOTE; HIV LONG-TERM SURVIVORS; HIV-1; HOMOZYGOTE; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOKINE;

EID: 0003184041     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001280-00004     Document Type: Article

References (26)

1. 1. D'Sousa MP, Harden VA. Chemokines and HIV-1 second receptors. Nature Med 1996, 2:1293-1300.
2. 2. Stewart G. Chemokine genes - beating the odds. Nature Med 1998, 4:275-277.
3. 3. Magierowska M, Theodorou I, Debre P, et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in Human Immunodeficiency Virus-1 - infected individuals. Blood 1999, 93:936-941.
4. 4. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996, 273:1856-1862.
5. 5. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
6. 6. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
7. 7. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T. HIV infection in an individual homozygous for the CCR5 deletion allele [letter]. Nature Med 1997, 3:252-253.
8. 8. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996, 2:1240-1243.
9. 9. Stewart GJ, Ashton LJ, Biti RA, et al. Increased frequency or CCR5Δ32 heterozygotes among long-term non progressors with HIV-1 infection. AIDS 1997, 11:1833-1838.
10. 10. Paxton WA, Liu R, Kang S, Wu L et al. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of β-chemokines. Virology 1998, 244:66-73.
11. 11. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997, 185:1681-1691.
12. 12. Mummidi S, Ahuja SS, McDaniel BL, Ahuja SK. The human chemokine receptor 5 (CCR5) gene: multiple transcripts with 5′ end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory region and non coding exons. J Biol Chem 1997, 272:30662-30671.
13. 13. Mummidi S, Ahuja SS, Gonzalez E, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nature Med 1998, 4:786-793.
14. 14. Rizzardi GP, Morawetz RA, Vicenzi E, et al. CCR2 polymorphism and HIV disease. Nature Med 1998, 4:252-253.
15. 15. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997, 277:959-965.
16. 16. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nature Med 1998, 4:350-353.
17. 17. McDermott DH, Zimmerman PA, Guinard F, Kleeberger CA, Leitman SF, the Multicenter AIDS Cohort Study (MACS) & Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 1998, 352:866-870.
18. 18. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998, 282:1907-1911.
19. 19. Ashton LJ, Carr A, Cunningham PL, et al. Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group. AIDS Res Hum Retroviruses 1998, 14:117-121.
20. 20. Liu R, Zhao X, Gurney TA, Landau NR. Functional analysis of the proximal CCR5 promoter. AIDS Res Hum Retroviruses 1998, 14:1509-1519.
21. 21. Moriuchi H, Moriuchi M, Fauci AS. Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry. J Immunol 1997, 159:5441-5449.
22. 22. Bream JH, Young HA, Rice N, et al. CCR5 promoter alleles and specific DNA binding factors. Science 1999, 284:222-223.
23. 23. Marianini R, Wong S, Mulder LCF, et al. CCR2 641 polymorphism is not associated with altered CCR5 expression or coreceptor function. J Virol 1999, 73:2450-2459.
24. 24. Deacon NJ, Tyskin A, Soloman A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-999.
25. 25. Monterfiori DC, Pantaleo G, Fink LM, et al. Neutralising and infection-enhancing antibody responses to human immunodeficiency virus type-1 in long-term nonprogressors. J Infect Dis 1996, 173:60-67.
26. 26. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T-cell and weak neutralising antibody responses in a subset of persons with stable non-progressing HIV-1 type-1 infection. AIDS Res Hum Retroviruses 1996, 12:585-592.